Abnormal Metabotropic Glutamate Receptor Expression and Signaling in the Cerebral Cortex in Diffuse Lewy Body Disease is Associated with Irregular α‐Synuclein/Phospholipase C (PLCβ1) Interactions
- 1 October 2004
- journal article
- research article
- Published by Wiley in Brain Pathology
- Vol. 14 (4) , 388-398
Abstract
Diffuse Lewy body disease (DLBD) is a degenerative disease of the nervous system, involving the brain stem, diencephalic nuclei and cerebral cortex, associated with abnormal α‐synuclein aggregation and widespread formation of Lewy bodies and Lewy neurites. DLBD presents as pure forms (DLBDp) or in association with Alzheimer disease (AD) in the common forms (DLBDc). Several neurotransmitter abnormalities have been reported including those of the nigrostriatal and mesocorticolimbic dopaminergic system, and central noradrenergic, serotoninergic and cholinergic pathways. The present work examines metabotropic glutamate receptor (mGluR) expression and signaling in the frontal cortex of DLBDp and DLBDc cases in comparison with age‐matched controls. Abnormal L‐[3H]glutamate specific binding to group I and II mGluRs, and abnormal mGluR1 levels have been found in DLBD. This is associated with reduced expression levels of phospholipase C β1 (PLCβ1), the effector of group I mGluRs following protein G activation upon glutamate binding. Additional modification in the solubility of PLCβ1 and reduced PLCβ1 activity in pure and common DLBD further demonstrates for the first time abnormal mGluR signaling in the cerebral cortex in DLBD. In order to look for a possible link between abnormal mGluR signaling and α‐synuclein accumulation in DLBD, immunoprecipitation studies have shown α‐synuclein/PLCβ1 binding in controls and decreased α‐synuclein/PLCβ1 binding in DLBD. This is accompanied by a shift in the distribution of α‐synuclein, but not of PLCβ1, in DLBD when compared with controls. Together, these results support the concept that abnormal α‐synuclein in DLBD produces functional effects on cortical glutamatergic synapses, which are associated with reduced α‐synuclein/PLCβ1 interactions, and, therefore, that mGluRs are putative pharmacological targets in DLBD. Finally, these results emphasize the emergence of a functional neuropathology that has to be explored for a better understanding of the effects of abnormal protein interactions in degenerative diseases of the nervous system.Keywords
This publication has 67 references indexed in Scilit:
- Abnormal α-synuclein interactions with rab3a and rabphilin in diffuse Lewy body diseaseNeurobiology of Disease, 2004
- Adenosine A1 receptor agonist treatment up-regulates rat brain metabotropic glutamate receptorsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2002
- Glutamate Receptor Dysregulation in the Hippocampus of Transgenic Mice Carrying Mutated Human Amyloid Precursor ProteinNeurobiology of Disease, 2001
- Possible Causes of Alzheimer's Disease: Amyloid Fragments, Free Radicals, and Calcium HomeostasisNeurobiology of Disease, 1998
- Cross-talk between β-adrenergic and metabotropic glutamate receptors in rat C6 glioma cellsBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1998
- Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganizationCurrent Biology, 1997
- Characterization of metabotropic glutamate receptors coupled to a pertussis toxin sensitive G-protein in bovine brain coated vesiclesFEBS Letters, 1993
- Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer's disease: an autoradiographic study of the hippocampusBrain Research, 1991
- Effect of monovalent ions upon G proteins coupling muscarinic receptors to phosphoinositide hydrolysis in the rat cerebral cortexEuropean Journal of Pharmacology: Molecular Pharmacology, 1990
- Cholinergic and Dopaminergic Activities in Senile Dementia of Lewy Body TypeAlzheimer Disease & Associated Disorders, 1990